[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 2 of about 2
1. Berney DM, Stankiewicz E, Adlan AM, Kudahetti S, Biedrzycki OJ, Hadway P, Watkin N, Corbishley C: DNA topoisomerase I and IIalpha expression in penile carcinomas: assessing potential tumour chemosensitivity. BJU Int; 2008 Sep;102(8):1040-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA topoisomerase I and IIalpha expression in penile carcinomas: assessing potential tumour chemosensitivity.
  • OBJECTIVE: To examine the tissue expression of DNA topoisomerase I (Topo I) and IIalpha (Topo II), to pursue the possibility of future chemotherapy regimens for squamous cell carcinoma of the penis (SCCP), as high expression of Topo I might indicate sensitivity to the camptothecins, whereas high Topo II might indicate sensitivity to etoposide.
  • Tumour stage, grade and type were available.
  • Tumour type was also strongly correlated with Topo II and Ki-67 expression, with the highest expression in basaloid carcinomas and the lowest in verrucous carcinomas.
  • CONCLUSION: The expression of Topo I is grade- and type-independent, and chemotherapy using the camptothecins is unlikely to be effective.
  • The strong positivity of Topo II in high-grade and basaloid SCCPs suggests that treatment with etoposide or other Topo II 'poisons' might be a better target for future clinical trials.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / enzymology. DNA Topoisomerases, Type I / metabolism. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Penile Neoplasms / enzymology
  • [MeSH-minor] Drug Resistance, Neoplasm. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489530.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down






Advertisement